Senzime Ab · OMXSTO:SEZI
Senzime Ab — Q2 2024 Earnings Presentation
18 slides from Senzime Ab's earnings presentation, Aug 26, 2024
Slide 1: Revolutionizing Perioperative Care. Q2 summary 2024
Revolutionizing Perioperative Care. Senzime develops precision-based patient monitoring solutions that drive a global paradigm shift in perioperative patient safety. Our portfolio, powered by proprietary smart algorithms, generates enhanced insights to safeguard every patient's journey, from anesthe
Slide 2: This is Senzime
This is Senzime • World-class technology used for precision- based monitoring of neuromuscular function to drive patient safety and reduce drug costs • In the midst of a market paradigm shift driving rapid growth, with commercial operations in over 30 markets and strong investor backing • Catalyzed
Slide 3: Senzime Q2 2024: Rapid growth continues
Senzime Q2 2024: Rapid growth continues Q2 revenues (MSEK) ”Strong growth in the US market, 16 we’re gaining market shares and 14 our technology is increasingly 12 being established as the new clinical standard in operating 10 11 rooms around the world” 8 4 6 14,9 76% 167% 4 1 Million SEK in Total s
Slide 4: We continue to be the fastest growing medical device company on Nasdaq Stockholm
We continue to be the fastest growing medical device company on Nasdaq Stockholm Net sales rolling-12 months (kSEK) Sales of TetraSens, rolling-12 months (kSEK) 48 000 28 000 26 000 44 000 24 000 40 000 22 000 36 000 20 000 32 000 18 000 28 000 16 000 24 000 14 000 20 000 12 000 10 000 16 000 8 000
Slide 5: Installed base of monitors grows, drives sales of disposable sensors
Installed base of monitors grows, drives sales of disposable sensors Total delivered base of TetraGraph-systems1 Shipped TetraSens disposable sensors (accumulated units) 3 000 350 000 2 632 48 680 (25 035) 300 000 TetraSens sensors sold 2 500 TetraGraphs during the quarter delivered to date 250 000
Slide 6: Senzime Q2 2024: Split of sales
Senzime Q2 2024: Split net sales per region (Q2) Split of sales Europe 14% RoW Currency 12% Reported adjusted Q2 2024 (kSEK) 2024 2023 Growth Growth USA 10 973 4 108 167% 163% Devices /other 5 189 1 160 347% 341% USA 74% Disposables 5 784 2 948 96% 93% Europe 2 167 2 216 -2% -2% Devices /other 549 1
Slide 7: TetraGraph customer (hospital) growth
TetraGraph customer (hospital) growth Number of active hospital accounts, end of period* 400 350 40 300 250 >370 New hospitals hospitals 200 in total in Q2 2024 150 100 50 0 Q1 2023 Q2 2023 Q2 2023 Q4 2023 Q1 2024 Q2 2024 * Excludes accounts in smaller distribution markets.
Slide 8: Q2 Highlights
Q2 Highlights Safeguarding Robotic Surgery Public tender GPO New European Kids wins winner Contract patent Senzime secures Senzime secures Senzime Wins Another Senzime signs its first Protection the unique contracts with multiple contracts within Major US Veterans GPO contract with noise cancelling
Slide 9: Secured Contract with the Most Prestigious and Highest Ranked Children's Hospital in the US
Secured Contract with the Most Prestigious and Highest Ranked Children’s Hospital in the US Followed a comprehensive competitive evaluation and once fully implemented, the TetraGraph system will be utilized in over 40 operating rooms. “This contract once again validates our position as the market le
Slide 10: EMG-technology proves to be superior to AMG in accuracy and precision
EMG-technology proves to be superior to AMG in accuracy and precision AMG-based devices EMG-based devices and reference MMG Substantial variation 27-51%* Minimal variation 0.3%* * Percentage of all train-of-four ratios that were outside range of 0.9 and 1.1 9
Slide 11: Quantitative neuromuscular monitoring eliminates residual blockade and is cost-effective
Quantitative neuromuscular monitoring proves once again it eliminates residual blockade and is cost-effective Two key conclusions • The US study with 189 patients showed that use of quantitative neuromuscular monitoring and reversal drug resulted in 0% occurrence of post- operative residual block •
Slide 12: New European Guidelines in Process: Monitoring Neuromuscular Blockade in Paediatric Patients
New European Guidelines in Process: Monitoring Neuromuscular Blockade in Paediatric Patients The task force’s goal is to present the guidelines during the ESAIC Congress in Presentation in Lisbon 2025. A Afshari, G Bonatti, N Disma, T Engelhardt, A Fuchs, T Fuchs-Buder, T Hansen, O Karam, J Karlsson
Slide 13: Growth and product market mix affects Gross Margin during quarter
Growth and product market mix affects Gross Margin during quarter Development of COGS (MSEK) and Gross Margin rolling-12 months (%) 40,0 80,0% 35,0 69,8% 70,0% 68,6% 68,7% 68,4% 67,2% 64,6% 62,0% 30,0 60,0% 57,4% 56,2% 53,7% 54,3% 53,2% 17,2 25,0 50,0% 48,2% 16,9 20,0 40,9% 40,2% 40,0% 16,6 16,3 16,
Slide 14: Sales growth with operating expense control
Sales growth with operating expense control Operating expenses including currency related effects (kSEK) 50 000 45 000 40 000 35 000 30 000 25 000 20 000 15 000 10 000 5 000 0 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 OPEX ecl. currenct effects OPEX incl currency effects
Slide 15: Updated Market Outlook and Long/Short Guidance
Updated Market Outlook and Long/Short Guidance 1. Rapidly expanding market 2. Market 3. Bold growth opportunity leadership ambitions Senzime estimates that the global market for Senzime’s mission is to be the Shorter-term guidance to reach EMG-based neuromuscular monitoring will undisputed global ma
Slide 16: Strong investor base secures Senzime's long-term plans
Strong investor base secures Senzime’s long-term plans As of June 30, 2024 Number of Capital Ten largest shareholders shares (%) Crafoord family and the Crafoord Foundation 20,222,151 16.9 Segulah Venture AB, Segulah AB, Segulah Medical Acceleration AB 12,803,271 10.7 Handelsbanken Fonder 7,712,201
Slide 17: Concluding comments
Concluding comments 1. The growth journey continues in an inflection point market with strong market demand driven by the guidelines published in 2023 2. Our technology is being established as the new clinical standard in operating rooms around the world 3. US commercial team secures major commercia
Slide 18: Revolutionizing perioperative care. Smart and simple.
Revolutionizing perioperative care. Smart and simple. Our mission is to safeguard every patient's journey, from anesthesia to recovery. We do this by developing user-friendly precision-based monitoring solutions, based on decades of science, that drive a perioperative digital transformation. Our com